Novel Modulators of Melanocortin Receptors for the Treatment of Depression and Anxiety

Technology #ua17-079

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Minying Cai
Research Professor, Chemistry and Biochemistry
Victor Hruby
Regents Professor Emeritus, Chemistry & Biochemistry
Managed By
Paul Eynott
Sr. Licensing Manager (520) 621-2878

Title: Novel Modulators of Melanocortin Receptors for the Treatment of Depression and Anxiety

 

Invention: The invention is the use of the melanocortin 5 receptor (MC5R) ligand to treat depressive and anxiety disorders. MC5R antagonism is the proposed mechanism of action.

 

Background: Depression and anxiety often have similar treatment, but experiencing the full effects of current pharmacotherapy can range from weeks to months. Antidepressants and anxiolytics are associated with a number of side effects including an increased risk of suicidal thoughts in those taking antidepressants. Therefore, a novel pathway is needed for rapid onset with minimal side effects.

 

Applications:

  • Pharmaceutical companies

 

Advantages:

  • Provides a treatment for depressive and anxiety disorders

 

Licensing Manager:

Paul Eynott

PaulE@tla.arizona.edu

(520) 471-3612